Amgen's skin cancer drug hits main goal in late-stage trial

03/20/2013 | Reuters

Sixteen percent of patients who took Amgen's experimental advanced melanoma drug talimogene laherparepvec experienced at least partial tumor shrinkage for six months, compared with 2% of patients who received subcutaneous granulocyte-macrophage colony-stimulating factor, preliminary data from a late-stage trial showed. A detailed look at the study is set for release at a medical meeting this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR